The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $787,500 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of California, Los Angeles (UCLA) on July 20, 2024. This grant supports UCLA's research investigating the RNA-binding protein ZFP36 and its role in regulating DNA repair and cell proliferation in pulmonary arterial hypertension (PAH). The key products and services to be delivered include:
- Analyzing large-scale genomic data from PAH patient lungs and cultured cells to identify ZFP36 targets and characterize their functions in PAH
- Conducting in-vitro experiments on PAH smooth muscle cells to validate the upregulation of ZFP36 targets, the role of ZFP36 in their regulation, and the impact on DNA repair and cell cycle
- Testing the effects of ZFP36 inhibition in an animal model of PAH to assess its potential therapeutic impact
By better understanding the regulatory mechanisms governed by ZFP36, this research aims to uncover new therapeutic approaches for the treatment of PAH, a debilitating cardiovascular disease. The grant will support the university's scientific investigations through May 2028.
Generated 3/18/25, 3:36 AM